Mesoblast and Novartis are working together on the analysis. I don’t think they will need to slice and dice to find positive results in the secondary endpoints. Anyway, when SI talks about recovery from other end organ damage, I think he is hinting that they are seeing this additional, remarkable, positive benefit that they hadn't even put in the secondary endpoints. Yes, that would be exploratory and would be looked at in a future trial, that result from this trial wouldn't be the basis for an approval.
I bring it up simply because I am hoping this is yet another way that Remestemcel-L can help heal and save lives. That's what all of this is about!
Anyway, we will all find out soon enough .
Ann: COVID ARDS Trial Topline 60-Day Results, page-1392
-
- There are more pages in this discussion • 237 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.015(1.04%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $3.815M | 2.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11031 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 14844 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |